DHFB
TXMD icon

Dixon Hubard Feinour & Brown’s TherapeuticsMD TXMD Stock Holding History

Dixon Hubard Feinour & Brown’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$0 Buy
51,532
+50,501
+4,898% +$482K ﹤0.01% 307
2022
Q1 		$20K Hold
1,031
– – ﹤0.01% 307
2021
Q4 		$18K Buy
+1,031
New +$30.9K ﹤0.01% 297

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Dixon Hubard Feinour & Brown's TXMD Position: Q2 2022 in Review

Dixon Hubard Feinour & Brown increased its TherapeuticsMD (TXMD) stake by 4,898% in Q2 2022, buying an estimated $482K and bringing the position to 51,532 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #307.

Dixon Hubard Feinour & Brown first reported a position in TXMD in Q4 2021 and has held it in 3 quarters since. The position peaked at $20K in Q1 2022. 53 funds tracked by Wall St. Rank hold TXMD as of Q2 2022.

  • Dixon Hubard Feinour & Brown held 51,532 shares of TherapeuticsMD worth $0 as of Q2 2022.
  • Dixon Hubard Feinour & Brown bought 50,501 TherapeuticsMD shares in Q2 2022, an estimated $482K.
  • TherapeuticsMD made up ﹤0.01% of Dixon Hubard Feinour & Brown's portfolio in Q2 2022, its #307 holding.
  • Dixon Hubard Feinour & Brown first reported a position in TherapeuticsMD in Q4 2021 and has held it in 3 quarters since.
  • Dixon Hubard Feinour & Brown's TherapeuticsMD position peaked at $20K in Q1 2022.
  • 53 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2022.

Based on Dixon Hubard Feinour & Brown's 13F filing for Q2 2022, filed 22 Jul 2022.